Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors
Conclusions: Ceritinib maximum-tolerated dose was 750 mg once daily in Japanese patients. Antitumor activity was observed irrespective of prior ALKi treatment history. Dose expansion, examining the activity of ceritinib in alectinib-resistant patients, is ongoing.
Source: Journal of Thoracic Oncology - Category: Cancer & Oncology Tags: Original Articles Source Type: research
More News: Cancer | Cancer & Oncology | Gastroenterology | Liver | Lung Cancer | Lymphoma | Non-Small Cell Lung Cancer | Study | Toxicology | Urology & Nephrology